Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | TP53 | P04637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.54 |
| ▸ | FPR1 | P21462 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433374 | 0.91 | FPR2 (0.56) | FPR2MAPTTP53SMN1; SMN2FPR1 | |
| SCHEMBL2405792 | 0.88 | THRB (0.61) | FPR2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL2407950 | 0.88 | CHKA (0.56) | FPR2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL14475642 | 0.87 | MAPT (0.59) | FPR2MAPTTP53LMNARXFP1 | |
| SCHEMBL2403437 | 0.87 | MAPT (0.57) | FPR2MAPTTP53 | |
| SCHEMBL2403990 | 0.86 | ESR2 (0.53) | FPR2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL2404836 | 0.86 | CHKA (0.57) | FPR2MAPTTP53LMNARXFP1 | |
| SCHEMBL14475948 | 0.86 | ESR2 (0.54) | FPR2MAPTTP53LMNARXFP1 | |
| SCHEMBL2404068 | 0.85 | KMT2A (0.56) | FPR2MAPTLMNASMN1; SMN2POLB | |
| SCHEMBL2405181 | 0.85 | MAPT (0.61) | FPR2MAPTLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381172-B2 | Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381172-B2 | Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381172-B2 | Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CLEM BRIAN | 2011-09-01 | — | — | US | disclosed |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CLEM BRIAN | 2011-09-01 | — | — | US | disclosed |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CLEM BRIAN | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CHKB, CHKA, CHAT | FPR2 4877/4885MAPT 1255/4885TP53 743/4885 |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | CHKB, CHKA, CHAT | FPR2 4863/4885MAPT 1122/4885TP53 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.